MannKind Corporation Participating at Upcoming Conferences
September 08 2020 - 8:00AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with diabetes and orphan lung
diseases, announced today that it will be participating at upcoming
conferences. Presenting from the Company will be its Chief
Executive Officer, Michael Castagna, PharmD.
- H.C. Wainwright 22nd Annual Global Investment Conference -
Fireside Chat on Monday, September 14, 2020 at 3:30 pm (EDT)
- 2020 Cantor Global Virtual Healthcare Conference - Fireside
Chat on Tuesday, September 15, 2020 at 8:40 am - 9:10 am
(EDT)
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
– Fireside Chat on Monday, September 21, 2020 at 10:50 am - 11:30
am (EDT)
Interested parties can access a link to the live webcast of the
presentations from the News & Events section of the Company's
website at http://www.mannkindcorp.com. The webcast replay will
remain available for 14 days following the live presentation.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and orphan
lung diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin in
the United States, where it is available by prescription from
pharmacies nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs field
sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
Company
Contact:818-661-5000ir@mannkindcorp.com
Source: MannKind Corporation
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024